<PAGE>
                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 205498

                                    FORM 10-Q

(Mark One)

         [ X ]   Quarterly report pursuant to Section 13 or 15(d) of the 
Securities Exchange Act of 1934. 
For the quarterly period ended March 31, 1999

                                       or

         [   ]   Transitional report pursuant to Section 13 or 15(d) of the 
Securities Exchange Act of 1934

For the transitional period from  _______________to_____________


Commission file number  0-29100
                        -------

                        PREMIER RESEARCH WORLDWIDE, LTD.
                        --------------------------------
             (Exact name of registrant as specified in its charter)

<TABLE>
<CAPTION>

<S>                                                               <C>       
                   Delaware                                       22-3264604
---------------------------------------------         -------------------------------------
(State or other jurisdiction of incorporation         (I.R.S. Employeer Identification No.)
               or organization)

           30 South 17th Street
             Philadelphia, PA                                        19103
---------------------------------------------         -------------------------------------
(Address of principal executive offices)                           (Zip Code)
</TABLE>

                                  215-972-0420
              (Registrant's telephone number, including area code)


                                       N/A
--------------------------------------------------------------------------------
              (Former name, former address and formal fiscal year,
                          if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports, and (2) has been subject to such filing
requirements for the past 90 days. X Yes
           No


Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

The number of shares of Common Stock, $.01 par value, outstanding as of May 12,
1999, was 7,114,720.

<PAGE>

                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES

                                      INDEX
<TABLE>
<CAPTION>
                                                                                                                       Page

Part I.  Financial Information
<S>                        <C>                                                                                          <C>
             Item 1.       Consolidated Financial Statements

                           Condensed consolidated balance sheets--March 31, 1999 (unaudited) and
                           December 31, 1998                                                                              3
                           Condensed consolidated statements of operations (unaudited)--Three Months
                           Ended March 31, 1999 and 1998                                                                  4

                           Condensed consolidated statements of cash flows (unaudited)--Three Months
                           Ended March 31, 1999 and 1998                                                                  5

                           Notes to condensed consolidated financial statements (unaudited)                             6-7


             Item 2.       Management's Discussion and Analysis of Financial Condition and Results of
                           Operations                                                                                  8-11

             Item 3.       Qualitative and Quantitative Disclosures about Market Risk                                    11

Part II. Other Information 
           
             Item 2.       Changes in Securities and Use of Proceeds                                                     12

             Item 6.       Exhibits and Reports on Form 8-K                                                              13

                           a.)      Exhibits

                                    10.24    Consulting Agreement between AmericasDoctor.com, Inc. and 
                                             Premier Research Worldwide

                                    27.0     Financial Data Schedule

                           b.)      Reports on Form 8-K

                                    None


Signatures                                                                                                               14

Exhibits                                                                                                                 

</TABLE>

                                        2
<PAGE>
                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                      (in thousands, except share amounts)

<TABLE>
<CAPTION>
                                                                March 31, 1999  December 31, 1998
                                                                --------------  -----------------
                                                                                   (unaudited)
ASSETS
<S>                                                                <C>              <C>     
Current assets:
 Cash and cash equivalents                                         $  8,769         $ 10,822
 Short-term investments                                               6,068            5,668
 Accounts receivable, net                                            12,283           10,423
 Prepaid expenses and other                                           1,342            2,176
 Deferred income taxes                                                  159              159
                                                                   --------         --------
   Total current assets                                              28,621           29,248

Property and equipment, net                                           4,588            4,110
Goodwill, net                                                         2,081            2,160
Other assets                                                          1,023            1,023
Deferred income taxes                                                 3,352            3,631
                                                                   --------         --------

                                                                   $ 39,665         $ 40,172
                                                                   ========         ========


LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
 Accounts payable                                                  $  2,448         $  2,519
 Accrued expenses                                                     1,421            1,156
 Deferred revenues                                                    4,395            5,556
                                                                   --------         --------
   Total current liabilities                                          8,264            9,231
                                                                   --------         --------
Commitments and contingencies

Stockholders' equity:
 Preferred stock-$10 par value, 500,000 shares authorized,
   none issued and outstanding                                           --               --
 Common stock-$.01 par value, 15,000,000 shares authorized,
   7,236,520 and 7,217,520 shares issued and outstanding                 72               72
 Additional paid-in capital                                          37,103           37,061
 Treasury stock, 177,800 shares at cost                                (779)            (779)
 Accumulated deficit                                                 (4,995)          (5,413)
                                                                   --------         --------

   Total stockholders' equity                                        31,401           30,941
                                                                   --------         --------

                                                                   $ 39,665         $ 40,172
                                                                   ========         ========
</TABLE>

         The accompanying notes are an integral part of these statements

                                        3


<PAGE>


                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands, except per share information)

<TABLE>
<CAPTION>
                                                         Three Months Ended March 31
                                                         ---------------------------

                                                         1999                   1998
                                                         ----                   ----
                                                                  (unaudited)
<S>                                                   <C>                    <C>     
Revenues                                              $ 12,287               $  8,013
Less-Reimbursed costs                                   (2,778)                (1,240)
                                                      --------               --------

Net revenues                                             9,509                  6,773
                                                      --------               --------

Costs and expenses:
     Direct costs                                        4,707                  2,758
     Selling, general and administrative                 3,740                  3,825
     Depreciation and amortization                         513                    343
                                                      --------               --------
Total costs and expenses                                 8,960                  6,926
                                                      --------               --------

Income (loss) from operations                              549                   (153)

Other income, net                                          148                    262

Income before income taxes                                 697                    109
Income tax provision                                       279                     44
                                                      --------               --------

Net income                                            $    418               $     65


Basic and diluted net income per share                $   0.06               $   0.01
                                                      ========               ========
</TABLE>



         The accompanying notes are an integral part of these statements




                                        4
<PAGE>


                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (in thousands)
<TABLE>
<CAPTION>
                                                                                   Three Months Ended March 31
                                                                                   ---------------------------
                                                                                       1999             1998 
                                                                                       ----             ----
                                                                                            (unaudited)
<S>                                                                                 <C>              <C>     
Operating activities:
Net income                                                                          $    418         $     65
Adjustments to reconcile net income to net cash
          provided by (used in) operating activities:
                Depreciation and amortization                                            513              343
                Provision for losses on accounts receivable                               30               --
                Deferred income taxes                                                    279               44
                Changes in assets and liabilities:
                    Accounts receivable                                               (1,890)            (644)
                    Prepaid expenses and other                                           834             (272)
                    Accounts payable                                                     (71)            (548)
                    Accrued expenses                                                     265              (97)
                    Deferred revenues                                                 (1,161)           1,693
                                                                                    --------         --------
                         Net cash provided by (used in) operating activities            (783)             584
                                                                                    --------         --------

Investing activities:
     Purchases of property and equipment                                                (912)            (609)
     Purchases of short-term investments                                                (400)              --
     Proceeds from sales of short-term investments                                        --            4,387
                                                                                    --------         --------
                         Net cash provided by (used in) investing activities          (1,312)           3,778
                                                                                    --------         --------

Financing activities:
     Net proceeds from exercise of stock options                                          42              534

Net increase (decrease) in cash and cash equivalents                                  (2,053)           4,896
Cash and cash equivalents, beginning of period                                        10,822            4,679
                                                                                    --------         --------

Cash and cash equivalents, end of period                                            $  8,769         $  9,575
                                                                                    ========         ========
</TABLE>


         The accompanying notes are an integral part of these statements


                                        5


<PAGE>

                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)

Note 1.       Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring adjustments) considered necessary for fair presentation have
been included. Operating results for the three month period ended March 31,
1999, are not necessarily indicative of the results that may be expected for the
year ending December 31, 1999. Further information on potential factors that
could affect the Company's financial results can be found in the Company's S-1
Registration Statement and its Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission.

Note 2.       Net Income per Share

The Company follows SFAS No. 128 "Earnings per Share". This statement requires
the presentation of basic and diluted earnings per share. Basic net income per
share is computed by dividing net income by the weighted average number of
shares of common stock outstanding during the year. Diluted net income per share
is computed by dividing net income by the weighted average number of shares of
common stock outstanding during the year, adjusted for the dilutive effect of
common stock equivalents, which consist primarily of stock options, using the
treasury stock method.

The table below sets forth the reconciliation of the numerators and denominators
of the basic and diluted net income per share computations. 
<TABLE>
<CAPTION>

Three Months Ended March 31,                                                                           Per
                                                        Net                                           Share
1999                                                  Income                    Shares                Amount
------------------------------------------------      ------                    ------                ------
<S>                                               <C>                           <C>                <C>        
Basic net income................................  $       418,000               7,049,000          $      0.06
Effect of dilutive shares.......................                                  108,000                  --   
                                                  ---------------             -----------          -----------

Diluted net income..............................  $       418,000               7,157,000          $      0.06  
                                                  ===============               =========          ===========


1998                                            
------------------------------------------------

Basic net income................................  $        65,000               7,082,000          $     0.01
Effect of dilutive shares.......................                                  146,000                  --   
                                                  ---------------             -----------          -----------

Diluted net income..............................  $        65,000               7,228,000          $      0.01  
                                                  ===============             ===========          ===========
</TABLE>

Options to purchase 215,635 and 300,983 shares of common stock were outstanding
at March 31, 1999 and 1998, respectively, but were not included in the
respective computations of diluted net income per share because the option
exercise prices were greater than the average market price of the Company's
common stock during the respective periods.



                                        6

<PAGE>

Note 3.            Comprehensive Income

The Company follows SFAS No. 130, "Reporting Comprehensive Income." The
Company's comprehensive income includes net income and unrealized gains and
losses from foreign currency translation and short-term investments. These
unrealized gains and losses were immaterial as of March 31, 1999 and 1998.

Note 4        Operating Segments

In June 1997, SFAS No. 131, "Disclosure about Segments of an Enterprise and
Related Information," was issued, effective for fiscal years ending after
December 15, 1998. The Company adopted this statement for the year ended
December 31, 1998. The Company's reportable segments are strategic business
units that offer different products and services to a common client base. The
segments are managed separately because each business requires different
technology.

The Company's products and services are provided through two business segments,
both in the United States and internationally: Clinical Operations, which
includes centralized diagnostic testing services, clinical trial management
services and clinical data management services; and Technology Operations, which
includes clinical trial and data management software, support and consulting
services. The Company's discontinued Phase I Clinical Research Unit and income
and expense not allocated to reportable segments are reported as Other.

The Company evaluates performance based on the net revenues and operating
earnings performance of the respective business segments.
<TABLE>
<CAPTION>

Segment information is as follows:

                                                               Three months ended March 31,1999
                                            -------------------------------------------------------------------
                                               Clinical
                                              Operations         Technology            Other           Total  
                                              ----------         ----------            -----           -----  
<S>                                           <C>                <C>                                 <C>       
Net revenues from external customers          $7,491,000         $2,018,000                 --       $9,509,000
Income from operations                           266,000            283,000                 --          549,000
Identifiable assets                           16,131,000          4,025,000         19,509,000       39,665,000

                                                              Three months ended March 31, 1998
                                            -------------------------------------------------------------------
                                               Clinical
                                              Operations         Technology            Other            Total   
                                              ----------         ----------            -----            -----   
Net revenues from external customers          $4,186,000         $2,513,000            $74,000       $6,773,000
Income (loss) from operations                   (676,000)           559,000            (36,000)        (153,000)
Identifiable assets                            8,001,000          3,434,000         26,986,000       38,421,000

</TABLE>




                                        7


<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

Overview

         The Company is a clinical research organization providing a broad range
of integrated product development services on a global basis to its clients in
the pharmaceutical, biotechnology and medical device industries. The Company's
products and services are provided, both in the United States and
internationally, through two business segments: Clinical Operations, which
includes centralized diagnostic testing services, clinical trial management
services and clinical data management services; and Technology Operations, which
includes the development, marketing and support of clinical trial and data
management software, support and consulting services. The Company had operated a
Phase I Clinical Research Unit, which was closed in the first quarter of 1998.

         The Company's centralized diagnostic testing services are on a
fee-for-service basis and contracts generally have terms of one month to two
years. A portion of the Company's fee frequently is paid upon contract execution
as a non-refundable up-front payment, with the remaining amounts billed monthly.
Clinical trial and data management services are generally fixed priced
contracts, with certain variable components, and range in duration from a few
months to two years. A portion of the Company's fee frequently is paid upon
contract execution as a non-refundable up-front payment, with the balance billed
in accordance with the contract terms. The Company's contracts generally may be
terminated with or without cause on 30 to 90 days notice. Clients terminate or
delay contracts for a variety of reasons, including, among others, the failure
of the product(s) being tested to satisfy safety or efficacy requirements;
unexpected or undesired clinical results of the product; the client's decision
to forego a particular study; insufficient patient enrollment or investigator
recruitment, and production problems resulting in shortages of required
supplies. Revenues from clinical trial software and services are derived
primarily from software license fees, software maintenance and support and
consulting services.

         Revenues from centralized diagnostic testing services are recognized as
the services are performed. Revenues from clinical trial and data management
services are generally recognized on a percentage of completion basis as work is
performed. The Company regularly subcontracts with third-party investigators in
connection with clinical trials and with other third-party providers for
specialized services. These and other reimbursable costs are paid by the Company
and reimbursed by clients and, in accordance with industry practice, are
included in revenues. Since reimbursed costs may vary significantly from
contract to contract and are not meaningful for analyzing trends in revenues,
they are included in gross revenues but excluded from net revenues.

         Revenues from technology software licenses are recognized upon shipment
of the software and related documentation when collectibility is deemed probable
and the license fee is deemed fixed and determinable. Revenues from software
maintenance and continuing support contracts are recognized on a straight-line
basis over the period in which the software maintenance and continuing support
is provided, generally twelve months. Revenues from consulting and training
services are recognized when the services are performed.

Results of Operations

Three months ended March 31, 1999 compared to three months ended March 31, 1998.

Net revenues for the three months ended March 31, 1999, increased $2,736,000 or
40.4 % to $9,509,000 compared to $6,773,000 for the three months ended March 31,
1998.

The Company experienced a strong increase in net revenues in its Clinical
Operations, which increased $ 3,305,000 or 79.0% to $7,491,000 for the period
ended March 31, 1999 compared to $4,186,000 for the same period in 1998. The
increase in net revenues was due to the Company's strong performance in
centralized diagnostic testing services which increased $1,638,000 or 88.3% to
$3,494,000 in the 1999 period from $1,856,000 in the 1998 period. In addition,
the Company's clinical trial and data management services net revenues increased
$1,667,000 or 71.5% to $3,997,000 for the three months ended March 31, 1999 from
$2,330,000 for the three months ended March 31, 1998. Overall, the increase in
net revenues for Clinical Operations resulted from revenues recognized from the
Company's contract backlog and new clinical contracts signed during the first
three months of 1999.


                                        8
<PAGE>

Net revenues for Technology Operations declined $495,000 or 19.7% to $2,018,000
for the three months ended March 31, 1999 from $2,513,000 for the three months
ended March 31, 1998. The decline in net revenues was due entirely to revenues
from significant software license and consulting contracts during the first
quarter of 1998 while comparable contracts did not occur during the first
quarter of 1999. Included in the net revenues for Technology Operations of the
three months ended March 31, 1999 was $575,000 in consulting revenues relating
to the Company's consulting contract with AmericasDoctor.com, Inc. (see
Liquidity and Capital Resources).

During the first quarter of 1998, the Company recorded net revenues of $74,000
from its Phase I unit, which was closed during that quarter.

Direct costs for the three months ended March 31, 1999 increased $1,949,000 or
70.7% to $4,707,000 from $2,758,000 for the three months ended March 31, 1998.
Direct costs, as a percentage of net revenues, increased to 49.5% for the three
months ended March 31, 1999 compared to 40.7% for the same period in 1998. The
increase in direct costs is due to increased staffing and subcontracting costs
to support client contract requirements and to accommodate projected future net
revenues. The increase in direct costs as a percentage of net revenues is due to
the increase in staff and subcontracting costs and to the mix of revenues as
Clinical Operations net revenues have a higher direct cost ratio than Technology
Operations net revenues.

Selling, general and administrative expenses declined slightly to $3,740,000 for
the three months ended March 31, 1999 from $3,825,000 for the three months ended
March 31, 1998. The decline in selling, general and administrative expenses is
due to personnel related and other expenses incurred in the first three months
of 1998 which were not incurred in the first three months of 1999. As a
percentage of net revenues, selling, general and administrative expenses were
39.3% for the first three months of 1999 compared to 56.5% for the first three
months of 1998. The decline in the percentage was due entirely to the
stabilization of expenses year to year and increasing net revenues.

Depreciation and amortization expense increased to $513,000 in the first quarter
of 1999 from $343,000 in the comparable 1998 quarter. The increase was due to
increased depreciation expense resulting from additional capital spending to
support the growth in net revenues.

Other income, which consists primarily of interest earned on the Company's cash,
cash equivalents and short-term investments, decreased to $148,000 from $262,000
for the three months ended March 31, 1999 and 1998, respectively. The decrease
is due to lower cash and short-term investment balances in 1999 as a result of
the Company's investment in AmericasDoctor.com, Inc., in July 1998, and general
uses of cash to support working capital and capital expenditure needs during
1998 and in the first quarter of 1999.

The Company's effective tax rate was 40.0% for the three months ended March 31,
1999 and 1998, respectively.

Liquidity and Capital Resources

For the three months ended March 31, 1999, the Company used cash in operations
of $783,000 compared to cash provided by operations of $584,000 for the three
months ended March 31, 1998. The year-to-year change was primarily the result of
increased accounts receivable and decreased deferred revenues, reflecting the
Company's increasing revenues, partially offset by increased net income and
cash provided by changes in other working capital accounts.

At March 31, 1999, the Company had $8,769,000 of cash and cash equivalents on
hand and $6,068,000 invested in short-term investments. The Company generally
places its investments in A1P1 rated commercial bonds and paper, municipal
securities and certificates of deposit with maturities of less than one year.

During the three months ended March 31, 1999, the Company purchased $912,000 of
equipment compared to $609,000 during the three months ended March 31, 1998. The
increase in equipment purchases reflects the additional capital equipment needed
to support the growth of the Company.


                                       9
<PAGE>

During the three months ended March 31, 1999, the Company received $42,000 in
cash from the exercise of 19,000 employee stock options.

On March 22, 1999, the Company announced that it had entered into a two-year,
$4.6 million consulting contract with AmericasDoctor.com, Inc. Under the terms
of the contract, the Company will provide consulting services to enhance this
internet company's capability to effectively support patient identification,
recruitment and referral to clinical investigational sites for both Premier
Research and other companies in the pharmaceutical, biotechnology and medical
device industries. The Company's consulting fees will be paid in eight equal
quarterly installments through December, 2000.

The Company has a line of credit with a bank, through June 30, 1999, that
provides for borrowings up to $3,000,000 at an interest rate of prime minus 35
basis points. The line of credit agreement includes certain covenants, the most
restrictive of which limit future indebtedness and require compliance with a
liabilities-to-tangible net worth ratio. To date, the Company has not borrowed
any amounts under its line of credit.

The Company expects that existing cash and cash equivalents, short-term
investments, cash flows from operations and borrowings under its line of credit
will be sufficient to meet its foreseeable cash needs for at least the next
year. However, there may be acquisition and other growth opportunities that
require additional external financing and the Company may from time to time seek
to obtain additional funds from the public or private issuances of equity or
debt securities. There can be no assurance that such financings will be
available or available on terms acceptable to the Company.

Year 2000

The Company is aware of the issues and problems associated with the Year 2000
date change. The Company has been addressing company-wide data processing and
infrastructure issues since 1995. Premier Research has undertaken a Year 2000
Compliance Plan that will be completed by September 1, 1999. In addition, the
Company also plans to have all clinical systems Year 2000 compliant by June 30,
1999. The purpose of this plan is to assure that Premier Research, as a
corporate entity, has assessed and taken appropriate actions necessary to become
compliant with any issues regarding Year 2000 requirements. The problems
surrounding Year 2000 compliance are of extreme concern to the Company, since
Premier Research is a clinical research organization providing diagnostic
testing and clinical research services to the pharmaceutical industry, as well
as a developer of clinical database management software. The Company produces
and delivers information that is date sensitive, especially in deriving date and
time calculations; Premier Research currently can provide to its clients, date
formats that contain century markers or 4-digit year fields for any of its
clinical and diagnostic information.

The Company's strategy to address Year 2000 compliance is to replace potentially
non-compliant software and hardware with new compliant systems or updated Year
2000 compliant versions. The inventory and assessment phases of the Year 2000
plan have primarily been completed for its hardware and software systems. The
Company has begun its remediation phase of the plan through the replacement and
updating of systems.

As of today over 90% of the Company's information technology infrastructure has
been assessed and found to be free from any Year 2000 issues. Those that have
shown not to be in compliance are currently being evaluated and renovated for
compliance. If a system can not be made compliant to the requirements, the
system will be replaced with one that is compliant.

The Company is also assessing its facilities worldwide that it leases or owns,
and plans to complete its deployment of applicable contingency plans by
September 1, 1999.

The Company is also assessing and surveying its suppliers of third party
products and services. Based upon information received from such parties, the
Company believes that most of its suppliers are developing, assessing and
remediating any issues associated with their Year 2000 plans. The Company cannot
at this time fully assess the status of its suppliers until they have completed
their own efforts. It will review the readiness of the suppliers on an on-going
basis throughout the remainder of the year and will implement specific actions
to rectify potential problems in its supply chain.

                                       10
<PAGE>

As with any other company in its industry or any business in general, the
Company is exposed to risks associated with failures in the private and public
sector to become Year 2000 compliant. These risks include the possibility that
public infrastructure systems, such as electricity, water, natural gas or
telecommunications may fail in this country and other countries in the world
that the Company does business. In addition, there are those risks that the
internal systems of the Company's suppliers, service providers and customers
will fail. The Company also relies considerably on travel and could be adversely
affected, if air and train travel is disrupted by issues related to the Year
2000.

The Company also relies heavily on the healthcare industry. This industry and
its related clinical investigational sites may not have focused their efforts on
the Year 2000 issue to the same degree. Thus the Company has an increased risk
that its investigational sites, necessary for the conduct of clinical trials,
will be unable to provide timely answers and data that it needs to perform
services on time to its contractual clients. Also, the failure of the Company's
customers to address the Year 2000 issue could negatively impact on their
ability to use the Company's services. While contingency plans will be developed
to address these risks, the Company cannot assure that those plans will
sufficiently protect the Company from the effects of those risks. Any
disruptions from the realization of any of these risks could adversely affect
the Company's ability to perform its services.

The Company estimates that the costs associated with its Year 2000 program will
be approximately $ 0.5 million, including costs already incurred. Total Year
2000 costs of approximately $0.3 million have been incurred by the Company
through March 31, 1999. The estimates of cost, timing and impact of addressing
the Year 2000 issue are based on numerous assumptions of future events,
including the continued availability of certain resources, the ability of the
Company to meet its deadlines and the cooperation of third parties. However,
there can be no guarantee that the assumptions will be correct and that these
estimates will be achieved. Actual results could differ significantly from those
expected by the Company.

Inflation

The Company believes the effects of inflation generally do not have a material
adverse effect on its results of operations or financial condition.

Cautionary Statement for Forward-Looking Information.

Statements included in Management's Discussion and Analysis of Financial
Condition and Results of Operations set forth above may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as competitive factors, technology development, market demand
and the Company's ability to obtain new contracts and accurately estimate net
revenues due to variability in size, scope and duration of projects, and
internal issues of the sponsoring client. Further information on potential
factors that could affect the Company's financial results can be found in the
Company's S-1 Registration Statement and its Reports on Form 10-K and 10-Q filed
with the Securities and Exchange Commission.

Item 3.       Qualitative and Quantitative Disclosures About Market Risk

The Company's primary financial market risks include fluctuations in interest
rates and currency exchange rates.

There have been no significant changes since December 31, 1998.

      
                                       11


<PAGE>

Part II.      Other Information

Item 2.       Changes in Securities and Use of Proceeds

(1)   Effective Date of Securities Act Registration Statement:  February 3, 1997
      registration No.:   333-17001

(2)   Offering Date:      February 4, 1997

(3)     Not Applicable

(4)   (i) The offering terminated after all shares registered were sold

      (ii)   Managing Underwriters:    Montgomery Securities
                                       Furman Selz
                                       Genesis Merchant Group

      (iii)  Class of Securities Registered: Common Stock
<TABLE>
<CAPTION>
      (iv)                                      Account of Company             Account of Selling Shareholder
                                                ------------------             ------------------------------
<S>                                             <C>                            <C>                 
             Amount Registered                  2,206,250 common stock         956,250 common stock

             Aggregate price of
             Amount Registered                  $37,506,250                    $16,256,250

             Amount Sold                          2,206,250                        956,250

             Aggregate Offering
             Price of Amount Sold               $37,506,250                     16,256,250

      (v)    Expenses of offering for account of the Company:
             Underwriting Discount and Commission                               $2,625,437
             Other expenses                                                       $698,813
             Total Expenses                                                     $3,324,250

             (A) There were no direct or indirect payments to directors, officers, general partners 
                 of the issuer or their associates; to persons owning ten (10) percent or more of common 
                 stock of the Company; or affiliates of the Company.

             (B) All of the above payments were direct or indirect payments to others not described in clause (A).

      (vi)   Net Offering Proceeds to the Company:                               $34,182,000

      (vii) Use of Proceeds as of March 31, 1999:
             Net cash paid for business acquisition:                               8,655,000
             Net cash paid for minority equity investment                          1,000,000
             Purchase of Equipment:                                                5,772,000
             Working Capital:                                                      3,919,000
             Temporary Investments (consisting of short-term,
             Investment-grade securities):                                         6,068,000

             All of the above payments were to others not described in item (v) (A) above.

      (viii) The use of proceeds is consistent with the Prospectus
</TABLE>

                                       12


<PAGE>


Item 6.  Exhibits and Reports on Form 8-K

             a.) Exhibits
                 10.24 Consulting agreement between AmericasDoctor.com, Inc. and
                       Premier Research Worldwide

                 27.0  Financial Data Schedule

             b.) Reports on Form 8-K

             None
















                                       13


<PAGE>
                                   Signatures


              Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.



                                       PREMIER RESEARCH WORLDWIDE, LTD.
                                                 (Registrant)

Date:         May 17, 1999             By:  /s/ Joel Morganroth         
                                            -----------------------------------
                                            Joel Morganroth, MD
                                            Chief Executive Officer




Date:         May 17, 1999             By:  /s/ Fred M. Powell    
                                            -----------------------------------
                                            Fred M. Powell
                                            Chief Financial Officer
                                            (Principal Financial and Accounting
                                            Officer)








                                       14


<PAGE>
The following exhibits are filed herewith, unless otherwise marked:

10.24  Consulting Agreement between AmericasDoctor.com, Inc. and Premier
       Research (filed herewith)

27.0   Financial Data Schedule (filed herewith)